TXG
10x Genomics, Inc.
TXG lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
TXG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Strong | |
| Unavailable |
TXG's cash flow is currently strong, and its revenue is stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
TXG PE Valuation
TXG has no meaningful PE right now: it lost money over the past year.
TXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TXG's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.52 | +$0.10 |
| Q2 2026 | -$0.59 | +$0.11 |
| Q1 2026 | -$0.17 | +$1.13 |
| Q4 2025 | -$0.35 | +$1.17 |
| Q3 2025 | -$0.62 | +$0.92 |
| Q2 2025 | -$0.70 | +$1.33 |
| Q1 2025 | -$1.30 | +$0.94 |
| Q4 2024 | -$1.52 | +$0.66 |
TXG is still losing money, but far less than before: $0.52 per share over the past year, against $5.37 at its worst in late 2020.
TXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $150.7M | +1.1% |
| Q2 2026 | $151M | -13% |
| Q1 2026 | $150.8M | -2.6% |
| Q4 2025 | $166M | +0.6% |
| Q3 2025 | $149M | -1.7% |
| Q2 2025 | $172.9M | +13% |
| Q1 2025 | $154.9M | +9.8% |
| Q4 2024 | $165M | -10% |
TXG's revenue fell from its 2023 peak and has held roughly level since: $151M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11% | +11 points |
| Q2 2026 | -13% | -30 points |
| Q1 2026 | -11% | +14 points |
| Q4 2025 | -12% | +18 points |
| Q3 2025 | -22% | +5.7 points |
| Q2 2025 | 17% | +45 points |
| Q1 2025 | -25% | +18 points |
| Q4 2024 | -30% | -0.2 points |
TXG's operating margin was −11% last quarter, up 11 points from the same quarter a year ago.
TXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.9M | -65% |
| Q2 2026 | $15.4M | -4.6% |
| Q1 2026 | $24.5M | -24% |
| Q4 2025 | $39M | +$48.5M |
| Q3 2025 | $42.5M | +140% |
| Q2 2025 | $16.1M | +249% |
| Q1 2025 | $32.5M | +$51.1M |
| Q4 2024 | -$9.5M | -142% |
TXG has burned cash in most quarters: $94M over the past year, up 15% from the year before.
TXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +822K shares |
| 1 year | +4.2% | +5.3M shares |
| 3 years | +11% | +13.1M shares |
| 5 years | +18% | +19.9M shares |
| Available history | +35% | +34M shares |
TXG has 131M diluted shares, up 4.2% from a year ago.
TXG Net Leverage
TXG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 28.5 | Neutral |
TXG's weekly RSI is 52 (neutral) and its Stochastic is 28 (neutral).
TXG PE vs Healthcare Sector
TXG has no meaningful PE right now: it lost money over the past year.
TXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.7 | 20% below |
| 20 week MA | $62.6 | 5.5% below |
| 50 week MA | $38.3 | 54% above |
| 100 week MA | $25.3 | 134% above |
| 200 week MA | $31.8 | 86% above |
TXG has slipped below its 8- and 20-week averages, though it's still 86% above its 200-week average.
TXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.2 | $151.3 | +94% |
| 2021 | $151.3 | $146.1 | -3.5% |
| 2022 | $146.1 | $34.2 | -77% |
| 2023 | $34.2 | $56.0 | +63% |
| 2024 | $56.0 | $14.6 | -74% |
| 2025 | $14.6 | $16.5 | +13% |
| 2026 YTD | $16.5 | $59.1 | +258% |
TXG is up 258% so far in 2026, after finishing lower in three of the previous six years.